Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

PEGylated Drugs Companies

PEGylation, the process of covalently attaching polyethylene glycol (PEG) to drugs, is a strategy used to improve the pharmacokinetic and pharmacodynamic properties of therapeutic agents. PEGylation can enhance the stability, solubility, and bioavailability of drugs, leading to improved therapeutic outcomes.

PEGylated Drugs Key CompaniesLatest PEGylated Drugs Companies Update



  • March 2023:

    A new GMP facility for the production of lipids for advanced pharmaceutical drug delivery applications has been established by Evonik at its location in Germany. In addition to the company's current laboratory and commercial production capacities, the 'lipid launch facility' can provide lipids for clinical and small-scale commercial manufacturing. Lipids manufactured on-site will be utilized in an extensive array of RNA and gene therapies, including protein replacement therapies, cancer immunotherapy, and infectious disease control. The lipid launch facility possessing particle engineering and purification capabilities, including chromatography, is capable of assisting clients in the manufacturing process of various types of proprietary and custom lipids. This includes phospholipids, ionizable cationic lipids, PEGylated lipids, and phospholipids.



  • August 2023:A biopharmaceutical company specializing in the production, development, and commercialization of recombinant therapeutic proteins generated via its proprietary ProCellEx® plant cell-based protein expression system, Protalix BioTherapeutics, Inc. disclosed financial results for the second quarter and furnished an update on recent corporate, regulatory, and clinical developments. Elfabrio® (pegunigalsidase alfa), a joint venture between the organization and its development and commercialization partner, Chiesi Global Rare Diseases (Chiesi), an organization of the Chiesi Group, has been granted regulatory approval in both the European Union (EU) and the United States (U.S.) for the management of Fabry disease in adult patients. The approved dosage is 1 mg^kg every two weeks. Elfabrio is a recombinant human α–Galactosidase–subtype enzyme replacement therapy (ERT) that is PEGylated.An enzyme engineered to possess an extended half-life and expressed in plant cell cultures. 


List of PEGylated Drugs Key companies in the market

  • Horizon Therapeutics Plc

  • F. Hoffmann-La Roche Ltd. 

  • Pfizer Inc. 

  • Novo Nordisk A/S 

  • UCB S.A. 

  • Amgen, Inc. 

  • AstraZeneca.  


  • Merck & Co., Inc.  


  • Takeda Pharmaceutical Company Limited 

  • Bayer AG 

  • Biogen 

  • BioMarin Pharmaceutical Inc 

  • Coherus BioSciences • Enzon • Leadiant Biosciences, Inc.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.